By expenditures
| Name | Title | Type |
|---|---|---|
| Alfred L. Norris | VICE PRESIDENT FOR BUSINESS & FINANCE | Auditee |
| Mary Morale | Vice President for Business and Finance | Auditee |
| James Clausell | Managing Partner | Auditee |
| Tony Clausell | Partner | Auditee |
| No contacts on file | ||
| ID | Year | Date Accepted | Auditor | Spend |
|---|---|---|---|---|
| 352009 | 2024 | 2025-03-31 | Clausell & Associates Cpa's PC | $13.77M |
| 301315 | 2023 | 2024-03-30 | Clausell & Associates Cpa's PC | $8.86M |
| 41737 | 2022 | 2023-05-24 | Clausell and Associates | $18.04M |
| Audit | Year | Accepted | Finding | Ref | Severity | Repeat | Requirement |
|---|---|---|---|---|---|---|---|
| 352009 | 2024 | 2025-03-31 | 1125133 | 2024-004 | Significant Deficiency | Yes | CL |
| 352009 | 2024 | 2025-03-31 | 1125132 | 2024-004 | Significant Deficiency | Yes | CL |
| 352009 | 2024 | 2025-03-31 | 1125131 | 2024-004 | Significant Deficiency | Yes | CL |
| 352009 | 2024 | 2025-03-31 | 1125130 | 2024-004 | Significant Deficiency | Yes | CL |
| 352009 | 2024 | 2025-03-31 | 1125129 | 2024-004 | Significant Deficiency | Yes | CL |
| 352009 | 2024 | 2025-03-31 | 1125128 | 2024-005 | Significant Deficiency | Yes | N |
| 352009 | 2024 | 2025-03-31 | 548691 | 2024-004 | Significant Deficiency | Yes | CL |
| 352009 | 2024 | 2025-03-31 | 548690 | 2024-004 | Significant Deficiency | Yes | CL |
| 352009 | 2024 | 2025-03-31 | 548689 | 2024-004 | Significant Deficiency | Yes | CL |
| 352009 | 2024 | 2025-03-31 | 548688 | 2024-004 | Significant Deficiency | Yes | CL |
| 352009 | 2024 | 2025-03-31 | 548687 | 2024-004 | Significant Deficiency | Yes | CL |
| 352009 | 2024 | 2025-03-31 | 548686 | 2024-005 | Significant Deficiency | Yes | N |
| 301315 | 2023 | 2024-03-30 | 966998 | 2023-004 | Significant Deficiency | Yes | CL |
| 301315 | 2023 | 2024-03-30 | 966997 | 2023-004 | Significant Deficiency | Yes | CL |
| 301315 | 2023 | 2024-03-30 | 966996 | 2023-004 | Significant Deficiency | Yes | CL |
| 301315 | 2023 | 2024-03-30 | 966995 | 2023-004 | Significant Deficiency | Yes | CL |
| 301315 | 2023 | 2024-03-30 | 966994 | 2023-005 | Significant Deficiency | - | N |
| 301315 | 2023 | 2024-03-30 | 390556 | 2023-004 | Significant Deficiency | Yes | CL |
| 301315 | 2023 | 2024-03-30 | 390555 | 2023-004 | Significant Deficiency | Yes | CL |
| 301315 | 2023 | 2024-03-30 | 390554 | 2023-004 | Significant Deficiency | Yes | CL |
| 301315 | 2023 | 2024-03-30 | 390553 | 2023-004 | Significant Deficiency | Yes | CL |
| 301315 | 2023 | 2024-03-30 | 390552 | 2023-005 | Significant Deficiency | - | N |
| 41737 | 2022 | 2023-05-24 | 623485 | 2022-004 | Significant Deficiency | Yes | CL |
| 41737 | 2022 | 2023-05-24 | 623484 | 2022-004 | Significant Deficiency | Yes | CL |
| 41737 | 2022 | 2023-05-24 | 623483 | 2022-004 | Significant Deficiency | Yes | CL |
| 41737 | 2022 | 2023-05-24 | 623482 | 2022-004 | Significant Deficiency | Yes | CL |
| 41737 | 2022 | 2023-05-24 | 623481 | 2022-004 | Significant Deficiency | Yes | CL |
| 41737 | 2022 | 2023-05-24 | 623480 | 2022-004 | Significant Deficiency | Yes | CL |
| 41737 | 2022 | 2023-05-24 | 47043 | 2022-004 | Significant Deficiency | Yes | CL |
| 41737 | 2022 | 2023-05-24 | 47042 | 2022-004 | Significant Deficiency | Yes | CL |
| 41737 | 2022 | 2023-05-24 | 47041 | 2022-004 | Significant Deficiency | Yes | CL |
| 41737 | 2022 | 2023-05-24 | 47040 | 2022-004 | Significant Deficiency | Yes | CL |
| 41737 | 2022 | 2023-05-24 | 47039 | 2022-004 | Significant Deficiency | Yes | CL |
| 41737 | 2022 | 2023-05-24 | 47038 | 2022-004 | Significant Deficiency | Yes | CL |